PL EN


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
Tytuł artykułu

Development and validation of a stability-indicating LC-UV method for the determination of doripenem and biapenem in pharmaceutical dosage forms

Identyfikatory
Warianty tytułu
Języki publikacji
EN
Abstrakty
EN
A stability-indicating LC assay method was developed and validated for the quantitative determination of doripenem and biapenem in pharmaceutical dosage forms in the presence of degradation products formed during forced degradation studies. An isocratic RP-HPLC method was developed with a C-18 (250 mm × 4.6 mm, 5 μm) column and 12 mM ammonium acetate-acetonitrile (96:4 υ/υ) as mobile phase. The flow rate of the mobile phase was 1.0 mL min-1 for doripenem and biapenem. The determination was carried out at the wavelength of 295 nm. The carbapenems were subjected to stress conditions of degradation in aqueous solutions including hydrolysis, oxidation, photolysis, and thermal degradation. The developed method was validated with respect to linearity, accuracy, precision, selectivity, and robustness.
Rocznik
Strony
207--219
Opis fizyczny
Bibliogr. 23 poz., rys., tab.
Twórcy
  • Poznan University of Medical Sciences Department of Pharmaceutical Chemistry, Faculty of Pharmacy Grunwaldzka 6 60-780 Poznań Poland
autor
  • PozLab Contract Research Organization Poznań Poland
autor
  • Poznan University of Medical Sciences Department of Pharmaceutical Chemistry, Faculty of Pharmacy Grunwaldzka 6 60-780 Poznań Poland
autor
  • Tanaka Laboratory in Hokkaido University W 7, Kita-ku Sapporo 060-8638 Japan
autor
  • Poznan University of Medical Sciences Department of Pharmaceutical Chemistry, Faculty of Pharmacy Grunwaldzka 6 60-780 Poznań Poland
Bibliografia
  • [1] M. Hikida, M. Mori, and T. Kitta, Chemotherapy, 42, 101 (1994)
  • [2] R.N. Jones, H.S. Sader, and T.H. Fritsche, Diagn. Microbiol. Infect. Dis., 52, 71 (2005)
  • [3] H.M. Wexler, A.E. Engel, D. Glass, and C. Li, Antimicrob. Agents Chemother., 49, 4413 (2005)
  • [4] C.M. Perry and T. Ibbotson, Drugs, 15, 2221 (2002)
  • [5] F. Walsh, Ther. Clin. Risk Manag., 3, 789 (2007)
  • [6] K. Ikawa, N. Morikawa, K. Ikeda, H. Ohge, and T. Sueda, Chemotherapy, 54, 386 (2008)
  • [7] J. Patel and S.E. Cook, Am. J. Health Syst. Pharm., 54, 412 (1997)
  • [8] R. Mendez, T. Alemany, and J.M. Villacorta, Chem. Pharm. Bull., 39, 831 (1991)
  • [9] M. Zając, J. Cielecka-Piontek, and A. Jelińska, J. Pharm. Biomed. Anal., 43, 445 (2007)
  • [10] J. Cielecka-Piontek, M. Zając, and A. Jelińska, J. Pharm. Biomed. Anal., 46, 52 (2008)
  • [11] A. Mendez, J. Dalomo, M. Steppe, and E. Schapoval, J. Pharm. Biomed. Anal., 41, 1363 (2006)
  • [12] Kayo, I. Kazuro, I. Aki, N. Yoshimi, M. Norifumi, J. Chromatogr. B, 844, 148 (2006)
  • [13] Kayo, I. Kazuro, M. Norifumi, K. Keiko, U. Nami, O. Hiroki, and S. Taijiro, J. Chromatogr. B, 867, 20 (2008)
  • [14] P.A. Psathas, K. Kuzmission, and S.Y. Ikeda, Clin. Ther., 30, 2075 (2008)
  • [15] X. Ming, H. Tai-Jun, Z. Fei, L. Xiao-Min, and X. Xiang-Yang, J. Biomed. Pharm. Anal., 49, 937 (2009)
  • [16] M. Bakshi, B. Singh, A. Singh, and S. Singh, J. Pharm. Biomed. Anal., 26, 891 (2001)
  • [17] ICH, Stability Testing of New Drug Substances and Products (Q1AR). International Conference on Harmonization, IFPMA, Geneva, 2000
  • [18] M. Bakshi, B. Singh, A. Singh, and S. Singh, J. Pharm. Biomed. Anal., 28, 1011 (2002)
  • [19] R. Sehrawat, M. Maithani, R. Singh, Chromatographia, 72, 1 (2010)
  • [20] J. Cielecka-Piontek, A. Lunzer, and A. Jelińska, Cent. Eur. J. Chem., 9, 35 (2011)
  • [21] J. Cielecka-Piontek and A. Jelińska, React. Kinet. Mech. Cat., 102, 37 (2011)
  • [22] J. Cielecka-Piontek and A. Jelińska, Spectrochim. Acta Mol. Biomol. Spectros., 77, 554 (2010)
  • [23] J. Cielecka-Piontek, K. Michalska, P. Zalewski, A. Jelińska, Cur. Pharm. Anal., 7, 213 (2011)
Typ dokumentu
Bibliografia
Identyfikator YADDA
bwmeta1.element.baztech-ea9a9c12-3464-4731-b544-aaeadc582eb1
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.